ArticlePloS one2017
Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Network toxicology, transcriptomics, and cytotoxic validation reveal TDCPP-induced pterygium mechanisms.Scientific reports · 2025Article
- Therapeutic Potential of Graphene Quantum Dots on Pterygium Cells.Investigative ophthalmology & visual science · 2025Article
- Matrix Metalloproteinases and Their Inhibitors in the Pathogenesis of Epithelial Differentiation, Vascular Disease, Endometriosis, and Ocular Fibrotic Pterygium.International journal of molecular sciences · 2025Review
- The Potential Role of Vitamin D in the Pterygium Pathophysiology-A Possible New Therapeutic Perspective and Narrative Review.Journal of clinical medicine · 2025Review
- Efficacy and survival outcomes of bevacizumab plus minocycline for glioblastoma.American journal of translational research · 2025Article
- Article
- Unravelling the molecular tapestry of pterygium: insights into genes for diagnostic and therapeutic innovations.Eye (London, England) · 2024Review
- Granzyme B Expression in Conjunctiva of Patients with Pterygium.International journal of molecular sciences · 2024Article
- Full thickness 3D in vitro conjunctiva model enables goblet cell differentiation.Scientific reports · 2023Article
- MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases.Cancers · 2022Article
- Response to: topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence.Arquivos brasileiros de oftalmologia · 2022Article
- Is Pterygium Morphology Related to Loss of Corneal Endothelial Cells? A Cross-Sectional Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).International journal of molecular sciences · 2020Review
- Clinical profile of pterygium in patients seeking eye care in India: electronic medical records-driven big data analytics report III.International ophthalmology · 2020Observational
- Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium.BioMed research international · 2019Article
- Effect of single subconjunctival injection of bevacizumab on primary pterygium: clinical, histopathological and immunohistochemical study.International journal of ophthalmology · 2018Article
- Unravelling the Contribution of Matrix Metalloproteinase-3 Genotype-Phenotype to Pterygium Risk.Cancer genomics & proteomicsArticle
- Comparison of Pterygium Recurrence with and without Using Postsurgical Topical Cyclosporin A 0.05%: A Randomized Clinical Trial.Journal of current ophthalmologyArticle
- Impacts of Matrix Metalloproteinase 9 Genotypes on Renal Cell Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygia tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs decreased their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.